What changed this week
Patterns across the week's 77 stories; each point names the stories it rests on.
- Treatment choices are increasingly linked to tumor or blood markers, supporting a shared testing service that helps match patients to targeted regimens.Stories 2, 4, 5, 31
- Cancer vaccine results diverged, with a melanoma vaccine reducing recurrence risk while BNT113 did not delay head and neck cancer progression; this raises the value of careful trial selection.Stories 26, 38, 63
- Shorter radiation schedules matched longer courses in two breast cancer settings, suggesting treatment burden can sometimes be reduced without worse reported outcomes.Stories 10, 42
- India access signals include a 30 per cent trade margin cap for 137 anti-cancer medicines, a CDSCO approval, and local CAR-T manufacturing collaboration; navigation could track these changes.Stories 23, 53, 54
- Early glioblastoma CAR-T studies reported median survival of 12.0 months and no delayed toxicities, while all patients had acute toxicities; local manufacturing efforts make this area worth monitoring.Stories 43, 50, 53
Precision oncology
- D2C7-ATC was tested in recurrent brain cancerStory 1
- Blood test linked to rucaparib outcomes in advanced prostate cancerStory 2
- Cobimetinib and vemurafenib showed activity in advanced thyroid cancerStory 3
- PIK3CA mutations were common in advanced endometrial cancerStory 4
- RAS mutations found in one in five people with acute myeloid leukemiaStory 5
- Tumor features linked to residual disease in multiple myelomaStory 15
- Higher eosinophil counts linked to lower breast cancer recurrenceStory 27
- Community practices adopt advanced testing and treatments for metastatic breast cancerStory 28
- Cancer actionability framework revised for precision oncologyStory 44
- Federal policy changes disrupt cancer disparities research, survey findsStory 45
- Ablation did not improve survival in oligometastatic breast cancerStory 55
- Researchers link nerve-related changes to pancreatic cancer growthStory 69
Clinical trials
- Shorter radiation course matched standard treatment for high-risk breast cancerStory 10
- Rusfertide improved treatment response in polycythemia veraStory 13
- Bavdegalutamide shrank prostate cancer marker in some patientsStory 31
- Shorter radiation matched standard treatment after breast cancer mastectomyStory 42
- Capivasertib improved time before prostate cancer grewStory 65
- Ribociclib improved disease-free outcomes in early breast cancerStory 66
- Radiation reduced local recurrence in high-risk pancreatic cancerStory 68
Cell and gene therapy
- Chimeric antigen receptor therapy helped in diffuse large B-cell lymphomaStory 25
- Bispecific Antibody-Based Holding/Bridging Therapy Before CAR-T in Aggressive B-Cell LymphomasStory 35
- CAR T-cell therapy shows no delayed toxicity in recurrent glioblastomaStory 43
- T-cell features linked to longer benefit from lymphoma CAR T therapyStory 67
- CD19 CAR-T Cell Therapy in Adults With Relapsed or Refractory B-Cell Acute Lymphoblastic Leukemia: A Phase I/II StudyStory 71
- Natalizumab for the Prevention of ICANS in Patients With Recurrent or Refractory Diffuse Large B-Cell Lymphoma or Mantle Cell Lymphoma Receiving CAR T-Cell TherapyStory 72
Antibody-drug conjugates
- Mocertatug rezetecan showed activity in ovarian cancerStory 16
- Becotatug Vedotin + Pucotenlimab+Platinum Induction and Sequential CCRT for Unresectable LA non-small cell lung cancerStory 36
- Becotatug Vedotin Plus Pucotenlimab for Metastatic Colorectal CancerStory 37
- Pembrolizumab trial tested treatment for muscle-invasive bladder cancerStory 64
- Single-arm, Multicenter, Open-label Phase II Study of Vedotin for Injection in Second-line or Later Treatment of Advanced Biliary Tract CancerStory 73
Cancer-care delivery
- Asian experts adapt guidance for early and locally advanced non-small-cell lung cancerStory 6
- Neighborhood disadvantage linked to worse early-onset colorectal cancer survivalStory 30
- Remote expert reviews changed care in cancer casesStory 46
- Financial incentives increased smoking abstinence among people referred for lung cancer screeningStory 56
India access
- Pan-Asian adapted ESMO Clinical Practice Guidelines for the diagnosis, treatment and follow-up of patients with early and locally advanced non-small-cell lung cancerStory 9
- NPPA caps trade margins at 30 per cent for 137 anti-cancer medicinesStory 23
- Nucelion Therapeutics, VeGen Bio collaborate on CAR-T cell therapy manufacturingStory 53
- Less Doses of Daratumumab Are Adequate to Achieve Response in Newly Diagnosed Multiple MyelomaStory 77
Cancer vaccines
- Cancer conference will examine how tumors evolve and resist treatmentStory 14
- BNT113 vaccine failed to delay head and neck cancer progressionStory 26
- Clinical Trial to Assess the Safety, Tolerability, Reactogenicity, and Immunogenicity of a 10 Valent Human Papillomavirus Virus (10vHPV) VaccineStory 59
- Moderna vaccine almost halves melanoma recurrence riskStory 63
Head and neck cancer
AI and cancer
Solid-tumor CAR-T
Radiopharmaceuticals
Other
- Ambient Artificial Intelligent Scribes in Oncology: Impact on Clinician Experience and Documentation BurdenStory 7
- Genome-wide CRISPR screen identifies mutation-specific pathways converging on TAZ/TEAD activation in mutant p53-driven breast cancerStory 8
- FDA approves Jemperli for some people with rectal cancerStory 11
- FDA approves dostarlimab for locally advanced rectal cancerStory 12
- Spatial Transcriptomics on a Diverse Pancreatic Cancer Cohort Reveals Race-Related Differences in Tumor Subtypes and Immune MicroenvironmentsStory 17
- FDA Approves Immunotherapy That May Allow Certain Patients with Rectal Cancer to Avoid Chemotherapy, Radiation and SurgeryStory 19
- FDA Approves Dostarlimab for MSI-H/dMMR Locally Advanced Rectal CancerStory 20
- Alpelisib Plus Olaparib in Platinum-resistant/Refractory, High-grade Serous Ovarian Cancer, With no Germline BRCA Mutation DetectedStory 21
- Pyronaridine in Acute Myeloid Leukemia (acute myeloid leukaemia)Story 22
- AIIMS doctors identify ‘Red Alert Zone’ to reduce risks in complex cancer surgeryStory 24
- MRI and PSMA PET/CT: Foes or friends for the early detection of prostate cancer?Story 32
- Selection and Management of Patients With Resectable Gastric or Gastroesophageal Junction Cancer Receiving Perioperative FLOT: A Modified Delphi Consensus ApproachStory 33
- Claudia Henschke, PhD, MD Finding Lung Cancer in TimeStory 34
- GUARD-LGG: a glioma upfront AI-driven radiotherapy response decipher for lower-grade gliomaStory 39
- ADP-A2M4CD8 Monotherapy and in Combination With Nivolumab in HLA-A2+ Subjects With MAGE-A4 Positive Ovarian Cancer (SURPASS-3)Story 40
- Study to Explore the Safety, Tolerability, and Pharmacokinetics of AMG 305 in Subjects With Advanced Solid TumorsStory 41
- Longitudinal circulating tumour DNA profiling reveals genomic risk and molecular response to bireociclib in advanced breast cancerStory 47
- ROR2-expressing acute myelogenous leukemia cells can be selectively targeted by anti-ROR2 CAR T cellsStory 48
- Towards reliable morphological subtyping and cancer detection on Barrett’s esophagus pathology through ensembling foundation modelsStory 49
- Platform Study of JDQ443 in Combinations in Patients With Advanced Solid Tumors Harboring the KRAS G12C MutationStory 51
- A Study of MK-1484 as Monotherapy and in Combination With Pembrolizumab (MK-3475) In Advanced or Metastatic Solid Tumors (MK-1484-001)Story 52
- Cancer theranosticsStory 57
- Research priorities to move circulating tumour DNA assays into clinical decision making in early-stage breast cancerStory 58
- A Study to Assess the Adverse Events and How Intravenously Infused Livmoniplimab in Combination With Budigalimab Moves Through the Bodies of Adult Chinese Participants With Locally Advanced or Metastatic Hepatocellular CarcinomaStory 62
- Linear cap-independent mRNA vaccines as an emerging vaccine platformStory 70
- Cancer cell-specific FOXP3 licenses MMP19-dependent matrix remodeling and metastatic dissemination in pancreatic ductal adenocarcinomaStory 74
- Subcutaneous Epcoritamab With or Without Lenalidomide as First Line Therapy for Diffuse Large B-Cell LymphomaStory 75
- A Study to Find a Suitable Dose of ASP4396 in Adults With Solid TumorsStory 76